Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), also known as Olema Oncology, is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of targeted therapies for women's cancers. Headquartered in San Francisco with operations in Cambridge, Massachusetts, Olema is advancing a pipeline of novel therapies aimed at improving treatment options for women living with cancer. The core focus of the company centers on endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.
Olema's lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). Palazestrant is currently in Phase 3 clinical trials under the OPERA-01 study for patients with recurrent, locally advanced, or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This innovative therapy has demonstrated significant potential by completely blocking ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer, showing anti-tumor efficacy, favorable pharmacokinetics, CNS penetration, and combinability with CDK4/6 inhibitors.
In addition to palazestrant, Olema is developing a potent KAT6 inhibitor (OP-3136), which addresses an epigenetic target implicated in breast cancer and other cancers. This compound has shown promise in preclinical studies and is expected to move into clinical trials by the end of 2024.
Olema's financial health remains robust, with cash, cash equivalents, and marketable securities totaling $249.0 million as of March 31, 2024. The company reported a net loss of $31.0 million for the first quarter of 2024, primarily driven by increased spending on research and clinical development activities. However, Olema continues to make significant strides in advancing its clinical programs, supported by experienced scientists, healthcare investors, and partnerships with innovative pharmaceutical companies.
Recent corporate highlights include the initiation of a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250, and the selection of a development candidate for the KAT6 program. Olema's commitment to transforming the standard of care for women's cancers is evident in its ongoing clinical studies and presentations at major oncology conferences such as the ESMO Breast Cancer Annual Congress.
For more information about Olema Pharmaceuticals, visit their website at www.olema.com.
Olema Oncology has appointed Dr. Naseem Zojwalla as Chief Medical Officer, succeeding Dr. Pamela Klein, who transitions to a senior advisory role. With over 15 years of oncology experience, Dr. Zojwalla will focus on advancing OP-1250, a promising therapeutic candidate for metastatic breast cancer, into Phase 2 trials. Dr. Bohen expressed confidence in Dr. Zojwalla's leadership during this critical phase, highlighting the significant potential of OP-1250 as a treatment option for women with breast cancer. The company aims to reshape standard care through innovative therapies.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 5:15 p.m. ET. The presentation will be led by President and CEO Sean P. Bohen, M.D., Ph.D. A live webcast can be accessed on Olema's website and will remain available for 14 days. Olema is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with its lead candidate, OP-1250, currently in a Phase 1/2 clinical trial for ER-positive breast cancer.
Olema Pharmaceuticals (Nasdaq: OLMA) reported promising results from the Phase 1 dose-escalation study of OP-1250, a novel treatment for metastatic breast cancer. Key findings included an overall response rate of 17% and a clinical benefit rate of 46% in patients on a recommended Phase 2 dose. Three partial responses were noted, with target lesions reduced by up to 100%. OP-1250 demonstrated favorable pharmacokinetics and tolerability. The company plans to advance into Phase 2 studies and combination trials in early 2022, bolstering its position in women’s cancer treatment.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) has issued a warning about falsified information circulating on social media regarding its planned poster presentation for the Phase 1 dose-escalation of OP-1250, part of an ongoing Phase 1/2 clinical trial at the San Antonio Breast Cancer Symposium. Olema clarifies that the unauthorized poster image was not released by the company. OP-1250 is being developed as a treatment for women with recurrent, locally advanced or metastatic ER-positive breast cancer.
Olema Pharmaceuticals (NASDAQ: OLMA) announced that it will present interim pharmacokinetic, safety, tolerability, and preliminary efficacy data for OP-1250, its investigational complete estrogen receptor antagonist, at the San Antonio Breast Cancer Symposium (SABCS) from December 7-10, 2021. The data, which will highlight OP-1250's potential in treating advanced or metastatic ER+/HER2- breast cancer, will be presented by experts on December 8 and 10. Additionally, an investor webcast will occur on December 8 at 8:30 a.m. ET, where Olema will review the Phase 1 clinical data for OP-1250.
Olema Pharmaceuticals (OLMA) announced the completion of the dose-escalation stage in its Phase 1/2 clinical trial for OP-1250, targeting metastatic, ER+/HER2- breast cancer. Interim data will be presented at the 2021 San Antonio Breast Cancer Symposium. The company plans to initiate a Phase 2 study and a Phase 1b trial with a CDK4/6 inhibitor in early 2022. Financially, Olema reported a Q3 net loss of $17.7 million, up from $7.8 million in 2020, with R&D expenses reaching $12.5 million, reflecting ongoing trial costs. Cash reserves total $306 million, sufficient until late 2023.
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on women's cancers, announced participation in two investor conferences this November. The events include the Jefferies London Healthcare Conference on November 16, 2021, at 5:00 p.m. GMT, and the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 11:45 a.m. ET. Live webcasts will be available on Olema’s website and archived for 14 days. Olema’s lead product, OP-1250, targets ER-positive breast cancer and is currently undergoing clinical trials.
Olema Pharmaceuticals (Nasdaq: OLMA) announced a poster presentation on OP-1250, a dual action therapy for metastatic breast cancer, at the virtual AACR-NCI-EORTC Conference from October 7-10, 2021. The presentation will detail an ongoing Phase 1/2 study of OP-1250, a complete estrogen receptor antagonist and selective degrader, targeting ER-positive, HER2-negative breast cancer. Preliminary data from the trial's dose escalation phase is expected in Q4 2021. Olema focuses on women's cancers, with OP-1250 as its leading candidate.
Olema Pharmaceuticals (Nasdaq: OLMA) announced a poster presentation featuring preclinical data on OP-1250, a complete estrogen receptor antagonist and selective ER degrader. This data will be showcased at the 1st JCA-AACR Precision Cancer Medicine International Conference, occurring virtually from September 10-12, 2021. The presentation, titled "Complete Estrogen Receptor (ER) Antagonism As An Optimal Approach for ER-Positive Breast Cancer Drug Development," will be available on-demand on the conference website. The company aims to advance targeted therapies for women’s cancers.
Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on targeted therapies for women's cancers, announced that Sean P. Bohen, M.D., Ph.D., CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 4:15 p.m. ET. A live webcast will be available on Olema's website and archived for 14 days.
Olema’s lead candidate, OP-1250, is currently under evaluation for its effectiveness in treating ER-positive, HER2-negative breast cancer in a Phase 1/2 clinical trial.
FAQ
What is the current stock price of Olema Pharmaceuticals (OLMA)?
What is the market cap of Olema Pharmaceuticals (OLMA)?
What is Olema Pharmaceuticals' primary focus?
What is OP-1250?
What stage is OP-1250 currently in?
What other therapies is Olema developing?
How is Olema's financial health?
Who supports Olema's research and development?
Where is Olema Pharmaceuticals headquartered?
What recent achievements has Olema made?
What is the significance of the OPERA-01 study?
Where can I find more information about Olema Pharmaceuticals?
